NEWPORT
BEACH, Calif., July 2, 2024
/PRNewswire/ -- Secada Medical, LLC dba Ventris Medical, a
privately held orthobiologics and tissue regeneration company, has
been granted a patent by the United States Patent and Trademark
Office for Producing an Osteoinductive Calcium Phosphate for Bone
Grafting. The invention relates to the treatment of biphasic
calcium phosphate granules to transform the standard post sintering
grain like surface morphology into a needle like surface morphology
shown to exhibit superior osteoinductivity.
Surface Morphology
The post processing surface morphology of the biphasic material
of the invention provides increased osteoinductivity and therefore
a superior artificial bone material suitable for a variety of
orthopedic treatments. The invention improves
osteoinductivity compared to pre-treated granules and may be used
to induce the formation of bone tissue in a patient alone or in
combination with growth factors, cells, or other components.
Multi-modal Application
The chemical processing methods of the invention can generate
the desired needle-like or nanorod-like surface morphology on any
ratio of calcium phosphate to apatite including β-tricalcium
phosphate to apatite including β-tricalcium
phosphate/hydroxyapatite (βTCP/HA) granules with less than 80% or
even 40% βTCP content.
Russell Cook, CEO of Ventris
Medical commented, "We continue to develop a robust library of
intellectual property that adds to our overall value
proposition. This technology, which we will commercialize as
Amplify® granules, will become a major component of our synthetic
bone graft offerings. It is our company mission to develop
next generational devices that bring excitement to our surgeon
community as well as our distribution partners."
John Brunelle, PhD, COO of
Ventris Medical added, "The Amplify technology platform is intended
to address critical gaps in current treatment algorithms while
bringing greater efficiency to the surgeon experience. Our
surface-activated granules combine the established clinical
efficacy of traditional biphasic materials with state-of-the-art
processing techniques, providing a bone graft that is more
synchronized with the natural healing process. This milestone sets
the stage for future product developments and establishes Ventris
as a key innovator in the ortho-biologics space."
About Ventris Medical
Ventris Medical is a leading medical device company focused on
developing innovative proprietary platforms for tissue regeneration
and bioresorbable bone graft products for a broad range of spinal
and orthopedic fusion procedures. For additional information
on Ventris Medical, please visit our website at
www.ventrismedical.com.
Media Contact:
Chris Zychek
chris@ventrismedical.com
View original
content:https://www.prnewswire.com/news-releases/ventris-medical-awarded-us-patent-for-producing-an-osteoinductive-calcium-phosphate-for-bone-grafting-302188181.html
SOURCE Ventris Medical